M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Health Benefits of Writing Therapy Among Asian American Cancer Survivors

Not Applicable

Recruiting

Conditions: Cancer

Interventions: Behavioral: Esays
Behavioral: Questionnaires

First Posted Date: 2024-04-16

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 192

Registration Number: NCT06367959

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy with Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)

Phase 2

Recruiting

Conditions: OligoProgressive Metastatic Disease

Interventions: Procedure: Next-line Systemic Therapy
Procedure: Local Consolidation Therapy

First Posted Date: 2024-04-16

Last Posted Date: 2024-12-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 300

Registration Number: NCT06367972

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of VG2025 Delivered Intraperitoneally in Patients with Advanced Solid Tumors with Carcinomatosis

Phase 1

Withdrawn

Conditions: Carcinomatosis
Advanced Solid Tumor

Interventions: Drug: VG2025

First Posted Date: 2024-04-15

Last Posted Date: 2024-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT06365918

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Phase 1

Recruiting

Conditions: Minimal Residual Disease
Colorectal Cancer

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Drug: Cetuximab
Drug: TROP2-CAR-NK Cells
Drug: Rimiducid (AP1903)
Procedure: Lymphodepleting Chemotherapy

First Posted Date: 2024-04-10

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT06358430

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Phase 2

Recruiting

Conditions: Splenomegaly
Myelofibrosis

Interventions: Drug: Ruxolitinib
Procedure: Allogeneic Stem Cell Transplantation
Drug: Levetiracetam
Drug: Eltrombopag
Drug: Busulfan
Drug: Romiplostim
Drug: Fludarabine phosphate
Drug: Cyclophosphamide
Drug: Mesna
Drug: Tacrolimus

First Posted Date: 2024-04-03

Last Posted Date: 2024-11-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06345495

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology

Phase 2

Recruiting

Conditions: Dyspnea

Interventions: Behavioral: SPOT-ON Early Start
Behavioral: SPOT-ON Delayed Start

First Posted Date: 2024-03-29

Last Posted Date: 2024-06-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT06336642

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

Phase 3

Recruiting

Conditions: Immune Checkpoint Therapy

Interventions: Other: Standard of care
Diagnostic Test: Troponin surveillance

First Posted Date: 2024-03-29

Last Posted Date: 2024-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 880

Registration Number: NCT06337097

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic

Recruiting

Conditions: Occupational Therapy
Cancer

Interventions: Other: Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)

First Posted Date: 2024-03-26

Last Posted Date: 2024-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT06329531

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Phase 2

Recruiting

Conditions: Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-Essential Thrombocytosis Myelofibrosis

Interventions: Drug: Tasquinimod
Drug: Ruxolitinib

First Posted Date: 2024-03-25

Last Posted Date: 2024-08-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT06327100

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Stage 1 cT1b-T1cN0M0
Triple Negative Breast Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Pembrolizumab
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2024-03-19

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT06318897

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy